Trial Profile

Phase 2 clinical stuidy of APVO436 in relapsed/refractory acute myeloid leukemia patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 16 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mipletamig (Primary) ; Azacitidine; Venetoclax
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Sponsors Aptevo Therapeutics

Most Recent Events

16 Aug 2023 New trial record
10 Aug 2023 According to an OmniAb media release, Aptevo intends to conduct this relapsed/refractory acute myeloid leukaemia patients beginning in the second half of 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com